Pfizer, Novartis Get Advisory Panel Backing For General Methods Of Meningococcal Vaccine Trials

Pfizer appears to be slightly ahead of Novartis in planning a Phase III clinical trial of a vaccine against meningococcal serogroup B, with an anticipated start date later this year.